Pyrrolo[2,3-D]pyrimidine compounds

Details Pyrrolo[2,3-D]pyrimidine compounds Pyrrolo[2,3-D]pyrimidine compounds

2009-08-28

2010-11-30

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S280000

Reexamination Certificate

active

07842699

ABSTRACT:
A compound of the formulawherein R1, R2and R3are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.

REFERENCES:
patent: 3037980 (1962-06-01), Hitchings et al.
patent: 5389509 (1995-02-01), Maskasky
patent: 5496946 (1996-03-01), Akimoto et al.
patent: 5686457 (1997-11-01), Traxler et al.
patent: 6080747 (2000-06-01), Uck{dot over (u)}n et al.
patent: 6136595 (2000-10-01), Ihle et al.
patent: 6180636 (2001-01-01), Traxler et al.
patent: 6187552 (2001-02-01), Roberds et al.
patent: 6310063 (2001-10-01), Ge et al.
patent: 6610847 (2003-08-01), Blumenkopf et al.
patent: 6627754 (2003-09-01), Blumenkopf et al.
patent: 6635762 (2003-10-01), Blumenkopf et al.
patent: 6696567 (2004-02-01), Blumenkopf et al.
patent: 6890929 (2005-05-01), Blumenkopf et al.
patent: 6956041 (2005-10-01), Blumenkopf et al.
patent: 6962993 (2005-11-01), Blumenkopf et al.
patent: 6965027 (2005-11-01), Flanagan et al.
patent: 7079208 (2006-07-01), Kim et al.
patent: 7091208 (2006-08-01), Blumenkopf et al.
patent: 7192963 (2007-03-01), Blumenkopf et al.
patent: 7265221 (2007-09-01), Blumenkopf et al.
patent: 7601727 (2009-10-01), Blumenkopf et al.
patent: 2003/0073719 (2003-04-01), Flanagen
patent: 2004/0058922 (2004-03-01), Blumenkopf
patent: 2004/0229923 (2004-11-01), Wilcox
patent: 2005/0159434 (2005-07-01), Flanagan
patent: 2005/0171128 (2005-08-01), Blumenkopf
patent: 2005/0197349 (2005-09-01), Blumenkopf
patent: 0334636 (1989-09-01), None
patent: 0795556 (1997-09-01), None
patent: 0682027 (1997-10-01), None
patent: 0915303 (1963-01-01), None
patent: WO9519774 (1995-07-01), None
patent: WO9802438 (1996-07-01), None
patent: WO9640142 (1996-12-01), None
patent: WO9702262 (1997-01-01), None
patent: WO9702266 (1997-01-01), None
patent: WO9713771 (1997-04-01), None
patent: WO9718212 (1997-05-01), None
patent: WO9727199 (1997-07-01), None
patent: WO9728161 (1997-08-01), None
patent: WO9732879 (1997-09-01), None
patent: WO9749706 (1997-12-01), None
patent: WO9802437 (1998-01-01), None
patent: WO9807726 (1998-02-01), None
patent: WO9823613 (1998-06-01), None
patent: WO9833798 (1998-08-01), None
patent: WO9951599 (1999-10-01), None
patent: WO9961428 (1999-12-01), None
patent: WO9965908 (1999-12-01), None
patent: WO9965909 (1999-12-01), None
patent: WO0000202 (2000-01-01), None
patent: WO0010981 (2000-03-01), None
patent: WO0017203 (2000-03-01), None
patent: WO0142246 (2001-06-01), None
patent: WO0200661 (2002-01-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Baird, A.M., et al.,J. Leukocyte Biology, “T Cell Development and Activation in JAK-3-Deficient Mice”, vol. 63, pp. 669-672 (1998).
Candotti, F., et al.,Springer Semin, Immunopathology, “Severe Combined Immune Deficiencies due to Defects in the Common y chain-JAK3 Signaling Pathway”, vol. 19, pp. 401-415 (1998).
Chen, E., et al.,Transplantation Proceedings“Advantage in Cytokine signaling: The Role of JAKs and STATs”, vol. 31, pp. 1482-1487 (1999).
Eynon, E.E., et al.,Journal of Interferon and Cytokine Research, “Disruption of Cytokine Signaling in Lymphoid Development: Unique Contributions of the Common Cytokine Gamma Chain and the JAK3 Kinase”, vol. 16, pp. 667-684 (1996).
Ghosh, S., et el.,Acta Crystallogr,.C:Crystal Structure Commun., “4-[(3-Bromo-4-hydroxyphenyl)amino]6,7-dimethoxyquinazolin-1-ium Chloride Methanol Solvate and 4-[(3-hydroxyphenyl)amino0-6,7-dimethoxy-1-quinazolinium Chloride”. vol. C57, pp. 76-78 (2001).
Hanke, J.H., et al.,Inflammation Research, “Role of Tyrosine Kiniases in Lymphocyte Activation: Targets for Drug Intervention”, vol. 44, pp. 357-371 (1995).
Ihie, J.N.,Advance Immunology, “The Janus Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling”, vol. 60, p. 1-35 1995.
Ihie, J.N.,Semin. Immunology, “The Janus Protein Tyrosine Kinases in Hematopoietic Cytokine Signaling”, vol. 7, p. 247 (1995).
Kirken, R.A., et al.,Cytokine, “Activation of JAK3, but not JAK1, is Critical for IL-2-Induced Proliferation and STAT 5 Recruitment by a Cooh-Terminal Region of IL-2 Receptor β-Chain”, vol. 7, pp. 689-700 (1995).
Liu, K.D., e t al.,Current Opinion of Immunology, “JAK/STAT Signaling by Cytokine Receptors”, vol. 10, pp. 271-278 (1998).
Li, X.C., et al.,Journal of Immunology, “Blocking the Common γ-Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-term Islet Allograft Survival”, vol. 164, pp. 1193-1199 (2000).
Leonard, W.J., et al.,Annual Review of Immunology, “JAKS and STATS: Biological Implications”, vol. 16, pp. 293-322 (1998).
Malaviya, R., et al.,J. Pharmacology and Experimental Therapeutics, “Treatment of Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with 4-(3-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97)”, vol. 295, No. 3 pp. 912-926 (2000).
Malaviya, R., et al.,Biochemical and Biophysical Research Communications, “Genetic and Biochemical Evidence for a Critical Role of Janus Kinase (JAK)-3 in Mast Cell-Mediated Type 1 Hypersensitivity Reactions”, vol. 257, pp. 807-813 (1999).
Malaviya, R., et al..Journal of Biological Chemistry, “Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis”, vol. 274(38), pp. 27028-27038 (1999).
Malabarba, M.G., et al.,Journal of Biological Chemistry, “Activation of JAK3, but not JAK1, is Critical to Interleukin-4(IL4) Stimulated Proliferation and Requires a Membrane-Proximal Region of IL4 Receptor α”, vol. 270(16), pp. 9630-9637 (1995).
Moriggi, R., et al.,Immunity, “Stat5 Activation is Uniquely Associated with Cytokine Signaling in Peripheral T Cells”, vol. 11, pp. 225-230 (1995).
Musso, T., et al.,Journal of Experimental Medicine, “Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukins 2, 4, and 7”, vol. 181, pp. 1425-1431 (1995).
Nelson, B.H., et al.,Proceedings of National Academy of Science USA, “Requirement for an Initial Signal from the Membrane-Proximal Region of the Interleukin 2 Receptor γcchain for Janus Kinsase Activation Leading to T Cell Proliferation”, vol. 94, pp. 1878-1883 (1997).
Notarangelo, L.D., et al.,Progressive in Immunodeficiency, “Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase”, vol. 6, pp. 61-68 (1996).
Oakes, S.A., et al.,Immunity, “Signaling via IL-2 and IL-4 in JAK3-DeficJent Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways”, vol. 5, pp. 605-615 (1996)
O'Shea, J.J., et al.,Nature, “Phosphorylation and Activation of the JAK-3 Janus Kinase in Response to Interleukin-2”, vol. 370(14), pp. 151-153 (1994).
Russell, S.M., et al.,Science, “Interaction of IL-2Rβ and γcChains with JAK1 and JAK3: Implications for XSCID and XCID”, vol. 266, pp. 1042-1045 (1994).
Sudbeck, E.A. et al.,Clinical Cancer Research, “Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-Inducing Antileukemic Agents”, vol. 5, pp. 1569-1582 (1999).
Sudbeck, E.A. et al.,IDrugs, “Recent Advances in JAK3 Kinase Inhibitors”, vol. 2(10), pp. 1026-1030 (1999).
Sudbeck, E.A., et al. Acta Cyrstallogr., SectC: Crystal Structure Communications “An Inhibitor of Janus Kinase 3: 4-(4-hydroxyphenynlamine)-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate”, vol. C56, pp. 1282-1283 (2000).
Thomis, D.C., et al.,The Jo

Affiliated with

Also associated with

Rating

Pyrrolo[2,3-D]pyrimidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolo[2,3-D]pyrimidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo[2,3-D]pyrimidine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4226846